Various case studies and clinical trials have demonstrated that there is less toxicity and prolonged progression-free survival from the use of PD-1 checkpoint blockade compared to CTLA-4, in advanced melanoma, for instance (187, 207). Here, PDCD1 is linked to melanoma.